Epigenomics (OTCMKTS:EPGNY – Get Free Report) and Natera (NASDAQ:NTRA – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Epigenomics and Natera, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Epigenomics | 0 | 0 | 0 | 0 | N/A |
| Natera | 0 | 0 | 6 | 0 | 3.00 |
Natera has a consensus target price of $70.22, indicating a potential upside of 23.39%. Given Natera’s higher probable upside, analysts plainly believe Natera is more favorable than Epigenomics.
Institutional & Insider Ownership
Profitability
This table compares Epigenomics and Natera’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Epigenomics | N/A | N/A | N/A |
| Natera | -54.97% | -88.47% | -41.19% |
Valuation and Earnings
This table compares Epigenomics and Natera’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Epigenomics | N/A | N/A | N/A | ($3.05) | -0.78 |
| Natera | $820.22 million | 7.95 | -$547.80 million | ($4.82) | -11.81 |
Epigenomics has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Epigenomics, indicating that it is currently the more affordable of the two stocks.
About Epigenomics
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
About Natera
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
Receive News & Ratings for Epigenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epigenomics and related companies with MarketBeat.com's FREE daily email newsletter.
